

# Analytical Methods

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1  
2  
3  
4 1 **A reusable and portable immunosensor using personal glucose**  
5  
6 2 **meter as the transducer**  
7  
8  
9  
10 3

11 4 Xi Zhu<sup>a,b</sup>, Huifeng Xu<sup>b,c</sup>, Hanye Zheng<sup>b</sup>, Yejian Han<sup>a</sup>, Guidi Yang<sup>a</sup>, Zhenyu Lin<sup>b\*</sup>,  
12  
13  
14 5 Longhua Guo<sup>b</sup>, Bin Qiu<sup>b</sup>, Guonan Chen<sup>b\*</sup>  
15

16  
17 6 *a* College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou, Fujian  
18  
19 7 350002, China  
20

21 8 *b* MOE Key Laboratory of Analysis and Detection for Food Safety, Fujian Provincial Key  
22  
23 9 Laboratory of Analysis and Detection Technology for Food Safety, Department of  
24  
25 10 Chemistry, Fuzhou University, Fuzhou, Fujian, 350002, China.  
26  
27

28 11 *c* Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine,  
29  
30 12 Fuzhou, Fujian, P. R. China  
31  
32

33 13  
34 14  
35 15  
36 16  
37 17  
38 18  
39 19  
40 20  
41 21  
42 22  
43 23  
44 24  
45 25  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

56  
57  
58 \* Corresponding author. Tel: +8659122866135; Fax: 86-591-22866135.  
59 E-mail: zylin@fzu.edu.cn (Z. Lin); gnchen@fzu.edu.cn (G. Chen).  
60

1  
2  
3 **Abstract**  
4

5 In this research, a portable immunosensor was developed using the personal glucose  
6 meter (PGM) as the signal transducer. In this system, the *anti-alpha-fetoprotein (anti-AFP)*  
7 is immobilized on the screen-printed gold electrode (SPGE) surface. The presence of  
8 target brought in the fixation of *invertase-anti-AFP* on *anti-AFP* modified SPGE, and  
9 then *invertase* catalyzed sucrose to glucose, which is detected using the PGM. The  
10 reading of the PGM exhibited a linear relationship with AFP concentration. The detection  
11 limit is 0.18 ng mL<sup>-1</sup>. After one test, this immunosensor can be reused at least 5 times by  
12 easy treatment. Moreover, the assay results of clinical serum samples are satisfactory.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

11 **Keywords:** Personal glucose meter; Screen-printed gold electrode; Immunosensor;  
12 Alpha-fetoprotein.

## 1 Introduction

2 Immunoassays have good applications in clinical diagnoses, environmental control and  
3 biochemical studies because of their good sensitivity and selectivity [1-3]. Various  
4 immunoassays have been reported, such as radiological immunoassays [4], fluorescence  
5 immunoassays [5, 6], surface plasmon resonance immunoassays [7, 8], quartz crystal  
6 microbalance immunoassays [9], enzyme-linked immunosorbent assays (ELISA) [10],  
7 chemiluminescence immunoassays [11] and electrochemical immunoassays [12-14].  
8 These immunsensors have been used successfully in the laboratory, which needs some  
9 bulky and expensive signal instruments for the measurement signals. And the results are  
10 output by the computers with professional software. Hence, it is difficult to apply online,  
11 even point-of-care due to their bulkiness and high cost.

12 The personal glucose meters (PGM), one of the most successful sensors, have been  
13 widely available in the personal family due to the portable “pocket” size, low cost,  
14 reliable quantitative results and simple operation [15]. Recently, Lu’s group [16, 17]  
15 combined the PGM with immunoassay to quantify disease biomarkers on the magnetic  
16 beads. This design is to transform the binding event between targets and their antibodies  
17 into a PGM-detectable signal, which expanded the range of PGM-detectable targets. Su et  
18 al. has also used the PGM for point-of-care early cancer diagnosis [18]. These strategies [16-  
19 18] used magnetic beads to immobilize DNA and antibody, which is able to separate and  
20 rinse. Unfortunately, using these strategies it is difficult to be reused. It will be great  
21 significance if these sensors can be reused by some easy treatments from the point of  
22 view of time and chemical reagents saving.

23 Here, a reused portable immunesensor using the PGM as the transducer is first  
24 developed. In this system, the conventional sandwich format is applied, and alpha-

1 fetoprotein (AFP), an oncofetal glycoprotein [19, 20], is chosen as a model. The primary  
2 antibody (*anti*-AFP) is immobilized on a screen-printed gold electrode (SPGE) surface. In  
3 the presence of AFP, *invertase* (*In*) labeled secondary *anti*-AFP antibody (*In-anti*-AFP)  
4 would attach on the SPGE surface, and then *In* molecule would catalyze sucrose to  
5 generate glucose, which is detectable using the PGM with the detection limit of 0.18 ng  
6 mL<sup>-1</sup>. Additionally, after the detection, this immunosensor can be reused by easy treatment,  
7 such as the interaction with the glycine-HCl buffer solution.

8 Compared with the previous immunosensors, this proposed method has some  
9 advantages: (1) it is portable without expensive and large size equipment, even  
10 connection with PC; (2) it is the first reproducible immunosensor based on the PGM; (3)  
11 the experimental process is simple without any separation. It is envisioned that this  
12 method not only expands the PGM application, but also supplies the support for the  
13 design of other portable sensors.

## 15 Experimental

### 16 Materials and chemicals

17 AFP standards, *anti*-AFP (clone 1G7, buffered aqueous solution) antibodies, were  
18 purchased from Biocell Biotechnol. Co., Ltd. (Zhengzhou, PRC). *Invertase* ( $\beta$ -  
19 fructosidase, from baker's yeast) and carboxymethyl dextran were acquired from Sigma-  
20 Aldrich (St. Louis, MO, USA). Other chemicals were of analytical grade and used  
21 without further purification. N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC)  
22 and N-Hydroxysuccinimide (NHS) were received from Shanghai Medpep Co., Ltd. All  
23 solutions were prepared using Milli-Q reagent water (Milli-Q, Millipore, 18.2-M $\Omega$

1  
2  
3 1 resistance). A sucrose solution (1 M) was prepared in the 40 mM Tris-HCl buffer solution  
4  
5 2 (pH 7.6) and stored at 4°C until used.  
6  
7

### 8 **Instruments**

9  
10 4 The SPGE (L3.3 cm×W1.0 cm×H0.05 cm) was purchased from eDAQ Technology  
11  
12 5 Corporation (Shanghai, China). It includes a gold working electrode (4 mm in diameter),  
13  
14 6 a silver reference electrode and a gold counter electrode. SPGE was prepared and  
15  
16 7 characterized using a CHI 660D electrochemical system (CH Instruments, Shanghai,  
17  
18 8 China) at room temperature. In the detection section, a commercially available glucose  
19  
20 9 meter (ACCU-CHECK Aviva) was used.  
21  
22  
23

### 24 **Synthesis of antibody-*invertase* conjugate**

25  
26  
27 11 The *invertase*-labeled secondary antibody (*In-anti*-AFP) was prepared according to the  
28  
29 12 previous report [21] with some minor modifications. Briefly, 50  $\mu$ L of *anti*-AFP ( $1.28 \times 10^{-}$   
30  
31 13  $^3$  M) was added into 40 mM Tris-HCl buffer solution (pH 7.6) containing invertase (33  
32  
33 14 mg/mL) and 5% glutaraldehyde. The mixture was incubated in 37 °C water bath for  
34  
35 15 overnight, and then dialyzed against Tris-HCl buffer solution to obtain antibody-*invertase*  
36  
37 16 conjugate Ab2.  
38  
39  
40

### 41 **Preparation of antibody-modified SPGEs**

42  
43 18 The immunosensor was prepared according to the previous report [22]. A clean  
44  
45 19 electrode was covered with 10  $\mu$ L of 50 mg/mL carboxymethyl dextran in distilled water  
46  
47 20 overnight at room temperature, and then washed with distilled water. 10  $\mu$ L EDC-NHS  
48  
49 21 solution containing 0.4 M EDC and 0.1 M NHS was then placed on the electrode surface  
50  
51 22 overnight. Next, 5  $\mu$ L *anti*-AFP was dropped on the above gold working electrode surface  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 under 60% humidity for 2 h. After blocking the possible remaining active sites using 2.0  
2 wt% BSA, the *anti*-AFP/SPGE was ready for target detection.

### 3 **Detection of target**

4 After dropping different concentrations of target antigen onto the *anti*-AFP/SPGE for 1  
5 h (Ag/*anti*-AFP/SPGE), 0.5 mL of *In-anti*-AFP was applied to obtain a sandwich-type  
6 structure immunosensor (*In-anti*-AFP/Ag/*anti*-AFP/SPGE). Next, 0.1 mL of sucrose  
7 solution was delivered on the immunosensor surface carefully, and then incubated in 45  
8 °C. 20 min later, 10 µL reacted sucrose solution was measured through a commercially  
9 available PGM, and the data from the PGM were collected for quantitative analysis.

### 10 **Reusable experiment**

11 After the assay, the immunosensor was immersed into 0.2 M glycine-HCl buffer  
12 solution (pH 2.8) for breaking the binding between antibody and antigen. And then, the  
13 regenerated immunosensor is used again.

## 15 **Results and Discussion**

### 16 **Principle of this immunosensor**

17 The principle of this immunosensor is shown in Figure 1. This sensor consists of target  
18 recognition and signal transducer, respectively. Target recognition is *anti*-AFP  
19 immobilized on the SPGE. Only in the presence of target, *In-anti*-AFP can attach on the  
20 electrode surface by antibody-antigen reaction to form the sandwich-type enzyme  
21 structure of *In-anti*-AFP/Ag/*anti*-AFP. With the assistance of *In*, sucrose would be  
22 catalyzed to generate glucose and fructose. Thus, glucose generated is detected using the  
23 PGM. Therefore, in this research the PGM can be used as signal transducer for the

1  
2  
3 1 monitor of target. Because of its small size and easy manipulation, the PGM is suitable to  
4  
5 2 develop the portable sensor. It is one of significant advantages of this biosensor. After one  
6  
7  
8 3 test, the glycine-HCl buffer solution (pH 2.8) was covered on the SPGE surface for  
9  
10 4 breaking the antibody-antigen interaction, and then the SPGE with *anti*-AFP is re-obtain  
11  
12 5 again, which achieves the regeneration of the sensor. It is another significant advantage of  
13  
14 6 this biosensor.

### 7 **Feasibility**

8 Control experiments have been done to certify the feasibility of the proposed principle.  
9 After incubation with 1 M sucrose solution for 20 min, the resulted solutions on different  
10 SPGEs are detected by the PGM. As shown in Figure 2, for *anti*-AFP/SPGE (histogram  
11 a), the PGM records “0 mM”, showing that there is no glucose generated; for *Ag/anti*-  
12 AFP/SPGE (histogram b) and *In-anti*-AFP/*anti*-AFP/SPGE (histogram c), the records are  
13 still “0 mM”, showing that in the presence of target antigen, no glucose is generated due  
14 to the lack of enzyme. While for *In-anti*-AFP/*Ag/anti*-AFP/SPGE (histogram d), the  
15 PGM records “7.5 mM”, displaying that 7.5 mM glucose is generated with the assistance  
16 of *In*. This result also indicates that *In* labeled on the antibody still sustains its catalytic  
17 activity. Additionally, the result of PGM can be estimated by the color indicator consisting  
18 of a round colored control window on the back of the test strip itself. In the presence of  
19 glucose, the color changes from yellow to green. In above three control experiments, the  
20 color does not change (strip a, b and c in inset), proving that there no glucose generated.  
21 While the formation of the sandwich-type enzyme structure of *In-anti*-AFP/*Ag/anti*-AFP  
22 would catalyze sucrose into glucose, resulting in the color change (strip d in inset).  
23 Therefore, it is feasible to use the PGM for the immunoassay.

24

## 1 **Optimized condition**

2 In order to obtain better results, some experimental conditions had been optimized.  
3 Firstly, the temperature and time of *invertase*-catalyzed sucrose had been studied. With  
4 the change of incubation temperature from 25 to 50 °C at the incubation time of 20 min,  
5 the signal of the PGM increases greatly and reaches a maximum at 45 °C (Figure 3A).  
6 The reason lies in that 45 °C is a suitable temperature for *invertase*. On the other hand,  
7 increasing the incubation time, the signal of the PGM enhances slowly (Figure 3B).  
8 Hence, 45 °C and 20 min are chosen as the optimal temperature and time for the reaction.

## 9 **Assay of target**

10 To study the relationship between the concentration of target and the signal of the  
11 PGM, targets with different concentrations are assayed using this proposed  
12 immunosensor, and the signals of the PGM recorded for the quantitative analysis. As  
13 shown in Figure 4A, with increasing target concentration, the signal of the PGM  
14 gradually increases. When target concentration exceeds 50 ng/mL, the PGM signal  
15 deviates from linearity and reaches a plateau at the max 33.3 mM, which is the upper  
16 limit of the PGM. The signal of the PGM has a linear relationship with the concentrations  
17 of target in the range of 0.5~50 ng mL<sup>-1</sup> (See the inset in Figure 4A), and the regression  
18 equation is

$$19 \quad Y=0.3624+6.222X \quad R=0.9996$$

20 where  $X$  is the concentration of AFP,  $Y$  is the signal of the PGM (mM),  $R$  is the  
21 regression coefficient. The detection limit is 0.18 ng mL<sup>-1</sup> based on  $3\sigma/\text{slope}$  ( $\sigma$  is the  
22 standard deviation of blank sample for 5 times), which performed better than those of  
23 electrochemical immunoassays [23, 24, 25] piezoelectric immunoassay [26],  
24 fluoroimmunoassay [27], microfluidic reflectometric interference spectroscopy [28].

1  
2  
3 1 Besides the record of the PGM for monitoring the target concentration, the colors from  
4  
5 2 the round colored control window are also related to the concentration of AFP (See  
6  
7  
8 3 Figure 4B).  
9

#### 10 4 **Selectivity**

11  
12 5 Herein, three proteins are used as interferents for the specific experiment, CEA, BSA  
13  
14 6 and lysozyme, respectively. The concentration of target is  $20 \text{ ng mL}^{-1}$ , while that of each  
15  
16 7 interferent is  $200 \text{ ng mL}^{-1}$ . As shown in Figure 5, in the presence of interferents, the PGM  
17  
18 8 displays in the range of “0 mM”~“0.5 mM”. While only in the presence of target, the  
19  
20 9 PGM records “14.1 mM”. This result shows that this method has good selectivity, and  
21  
22  
23 10 interference from some interferents can be ignored.  
24  
25  
26

#### 27 11 **Reusability and repeatability**

28  
29 12 After the assay, the used electrode is immersed into the glycine-HCl buffer solution  
30  
31 13 (pH 2.8) for 1 hr to break the antibody-antigen linkage, and then carried out the repeated  
32  
33 14 assay step. After 5 repeated experiments, the reading of the PGM retains 80 % of the  
34  
35 15 original signal, and the RSD of 5 experiments is 5 %. This result shows that this method  
36  
37 16 has good reusability. In addition, 3 gold electrodes were cleaned for the same experiments  
38  
39 17 as above as parallel experiments. The similar results are achieved with RSD of 6.5%,  
40  
41 18 indicating that this method has good repeatability.  
42  
43  
44

#### 45 19 **Analysis of clinical serum samples**

46  
47 20 To validate this method in the real-life samples, three clinical serum samples (provided  
48  
49 21 available by Fujian Provincial Hospital, China) are assayed. The results are shown in  
50  
51 22 Table 1. The concentrations of AFP in the serum samples are  $2.4$  and  $4.5 \text{ ng mL}^{-1}$ ,  
52  
53 23 respectively, which is similar with the reference results from the hospital, and the  
54  
55  
56  
57  
58  
59  
60

1 recoveries of this proposed method are between 90%~105%, showing that it has a  
2 satisfactory accuracy.

### 3 **Conclusion**

4 In summary, a reused portable immunosensor using the PGM as the transducer was  
5 demonstrated. The recognition event between antibody and antigen can be monitored  
6 using the PGM, and it is found that the record of the PGM has a relationship with the  
7 concentration of target AFP with the detection limit of 0.18 ng/mL (S/N=3). In addition,  
8 this proposed sensor has good reusability, and is followed by assays of AFP in serum  
9 samples with the satisfactory results. More importantly, because the transducer is small  
10 and portable, hence, it is possible for public to do diagnosis and detections in personal  
11 family.

### 12 **Acknowledgement**

14 This project was financially supported by the National Basic Research Program of  
15 China (No.2010CB732403), NSFC (21305014, 21175024, 41076059), SRF for ROCS,  
16 SEM (LXKQ201102), the Program for New Century Excellent Talents in Fujian Province  
17 University (JA10011), Key Subject of Ecology, Fujian Province (6112C0600) and the  
18 Program for Changjiang Scholars and Innovative Research Team in University (No.  
19 IRT11116).

### 20 **References**

- 22 1 T. McGlinchey, P. Rafter, F. Regan, G. McMahon. *Anal. Chim. Acta*, 2008, 624, 1-15.
- 23 2 T. Henarea, F. Mizutani, H. Hisamoto. *Anal. Chim. Acta*, 2008, 611, 17-30.

- 1  
2  
3 1 3 R. Cui, H. Pan, J. Zhu, H. Chen. *Anal. Chem.*, 2007, 79, 8494-8501.  
4  
5  
6 2 4 J. E. Causse, I. Ricordel, M. N. Bachelier, F. Kaddouche, B. Nom, R. Weil, B.  
7  
8 3 Descomps, J. P. Yver. *Clin. Chem.*, 1990, 36, 525-528.  
9  
10 4 5 J. Tang, D. P. Tang, R. Niessner, G. N. Chen, D. Knopp. *Anal. Chem.*, 2011, 83, 5407-  
11  
12 5 5414.  
13  
14 6 6 L. Liu, X. Dong, W. Lian, X. Peng, Z. Liu, Z. He, Q. Wang. *Anal. Chem.*, 2010, 82,  
15  
16 7 1381-1388.  
17  
18 8 7 M. Schelhaas, E. Nägele, N. Kuder, B. Bader, J. Kuhlmann, A. Wittinghofer, H.  
19  
20 9 Waldmann. *Chem. Eur. J.*, 1999, 5, 1239-1252.  
21  
22 10 8 K. Stembera, S. Vogel, A. Buchynskyy, J. A. Ayala, P. Welzel. *ChemBioChem*, 2002,  
23  
24 11 3, 559-565.  
25  
26 12 9 K.S. Yun, B. Kobatake, T. Hamyama, M. L. Laukkanen, K. Keinanen, M. Arizawa,  
27  
28 13 *Anal. Chem.*, 1998, 70, 260-264.  
29  
30 14 10 G. Zhou, J. Ireland, P. Rayman, J. Finke, M. Zhou. *Urology*, 2010, 75, 257-261  
31  
32 15 11 Z. Yang, H. Liu, C. Zong, F. Yan, H. Ju. *Anal. Chem.*, 2009, 81, 5484-5489.  
33  
34 16 12 K. Kerman, N. Nagatani, M. Chikae, T. Yuhi, Y. Takamura, E. Tamiya. *Anal. Chem.*  
35  
36 17 2006, 78, 5612-5616.  
37  
38 18 13 N. Martinez, R. Schneider, G. Messina, J. Raba. *Biosens. Bioelectron.*, 2010, 25, 1376-  
39  
40 19 1381.  
41  
42 20 14 X. Zheng, C. Li. *Biosens. Bioelectron.*, 2010, 25, 1548-1552.  
43  
44 21 15 A. E. Carroll, D. G. Marrero, S. M. Downs. *Diabetes Technol. The.*, 2007, 9, 158-164.  
45  
46 22 16 Y. Xiang, Y. Lu. *Nat. Chem.*, 2011, 697-703.  
47  
48 23 17 Y. Xiang, Y. Lu. *Anal. Chem.*, 2012, 84, 4174-4178.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 1 18 J. Su, J. Xu, Y. Chen, Y. Xiang, R. Yuan, Y. Q. Chai, *Chem. Commun.*, 2012, 48,  
4  
5 6909-6911.  
6  
7  
8 3 19 E. Alpert, R. Hershberg, P.H. Schur, K.J. Lsselbacher. *Gastro-enterology*, 1971, 61,  
9  
10 137.  
11  
12 5 20 Yamagata, Y., Katoh, H., Nakamura, K., Tanaka, T., Satomura, S., Matsuura, S. J.  
13  
14 *Immunol. Meth.* 1998, 212, 161.  
15  
16  
17 7 21 K. Mera, M. Nagai, J. W. C. Brock, Y. Fujiwara, T. Murata, T. Maruyama, J. W.  
18  
19 Baynes, M. Otagiri, R. Nagai, *J. Immunol. Methods*, 2008, 334, 82-90.  
20  
21  
22 9 22 F. Salam, I. E. Tothill. *Biosens. Bioelectron.*, 2009, 24, 2630-2636.  
23  
24  
25 10 23 H.L. Qi, C. Ling, Q.Y. Ma, Q. Gao, C.X. Zhang. *Analyst*, 2012, 137, 393-399  
26  
27  
28 11 24 J. Tang, B.L. Su, D.P. Tang, G.N. Chen. *Biosens. Bioelectron.*, 2010, 25, 2657-2662  
29  
30  
31 12 25 J. Tang, D.P. Tang, B.L. Su, Q.F. Li, B. Qiu, G.N. Chen. *Analyst*, 2011, 136, 3869-  
32  
33 3871  
34  
35  
36 14 26 L. Su, L. Zou, C.C. Fong, W.L. Wong, F. Wei, K.Y. Wong, R.S.S. Wu, M. Yang.  
37  
38 *Biosens. Bioelectron.*, 2013, 46, 155-161  
39  
40  
41 16 27 M.J. Chen, Y.S. Wu, G.F. Lin, J.Y. Hou, M. Li, T.C. Liu. *Anal. Chim. Acta*, 2012, 741,  
42  
43 100-105  
44  
45  
46 18 28 Y. Kurihara, M. Takama, T. Sekiya, Y. Yoshihara, T. Ooya, T. Takeuchi. *Langmuir*,  
47  
48 2012,28,13609-13615.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1

2

3

4

5

**6 Figure Captions**

7 **Figure 1** Sensing principle and regeneration of the portable immunosensor using the  
8 PGM.

9 **Figure 2** The signals of the PGM under different condition. a: *anti*-AFP/SPGE; b:  
10 *Ag/anti*-AFP/SPGE; c. *In-anti*-AFP/*anti*-AFP/SPGE; d. *In-anti*-AFP/*Ag/anti*-AFP/SPGE.  
11 Inset: the corresponding color changes of the round control window on the back of the  
12 test strip upon above conditions.

13 **Figure 3** (A) Effect of the catalyze temperature on the readout of PGM. (B) The  
14 optimization of incubation time between invertase and sucrose. The concentration of  
15 sucrose is 1 M.

16 **Figure 4** (A) Calibration curve between AFP concentrations and the signals of the PGM,  
17 from 1 to 8, the concentrations of AFP are 0.5, 1.0, 3.0, 8.0, 20.0, 30.0, 50.0 and 100.0 ng  
18 mL<sup>-1</sup>. (B) The corresponding color changes of the round control window on the back of  
19 the test strip with the increasing the concentration of AFP.

20 **Figure 5** Selectivity of the portable immunosensor toward other proteins, containing CEA,  
21 BSA, and Lysozyme. Their concentrations are 200 ng mL<sup>-1</sup>, while target concentration is  
22 20 ng mL<sup>-1</sup>.

23

24

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60**Table 1** Evaluation of this portable immunosensor in clinical serum specimen

Sample	Detected Result (ng mL <sup>-1</sup> )	Reference Result (ng mL <sup>-1</sup> )	Detectio		
			Add AFP (ng mL <sup>-1</sup> )	n after Addition (ng mL <sup>-1</sup> )	Recovery (%)
1	2.4	2.6	2	4.2	90
			4	6.3	97.5
			8	10.5	101.3
2	4.5	4.1	2	6.6	105
			4	8.8	91
			8	12.2	96.3
3	5.4	5.0	2	7.5	105
			4	9.4	100
			8	12.9	93.8
4	3.3	3.7	2	5.4	105
			4	7.4	102.5
			8	11.2	98.8

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1




Figure 2

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6




Figure 3

7  
8  
9  
10  
11  
12  
13  
14

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6




Figure 5

7  
8  
9

Analytical Methods Accepted Manuscript